Table 4

Lymph node involvement in endometrioid (A) and serous (B) endometrial cancer, after combining Mayo Clinic, European Institute of Oncology, and Memorial Sloan Kettering Cancer Center (Mueller et al.9 2020) cohorts

(A)
ParameterGrade 1 (n=1488)Grade 2 (n=606)Grade 3 (n=224)Total (n=2318)
ITCMicro/MacroITCMicro/MacroITCMicro/MacroITCMicro/Macro
No MI invasion2/676 (0.3)0/676 (0.0)1/108 (0.9)0/108 (0.0)0/42 (0.0)2/42 (4.8)3/826 (0.4)2/826 (0.2)
<50% MI38/655 (5.8)16/655 (2.4)17/331 (5.1)16/331 (4.8)5/96 (5.2)5/96 (5.2)60/1082 (5.5)37/1082 (3.4)
≥50% MI33/157 (21.0)21/157 (13.4)21/167 (12.6)38/167 (22.8)12/86 (14.0)16/86 (18.6)66/410 (16.1)75/410 (18.3)
Column total73/1488 (4.9)37/1488 (2.5)39/606 (6.4)54/606 (8.9)17/224 (7.6)23/224 (10.3)129/2318 (5.6)114/2318 (4.9)
(B)
ITCMicro/Macro
No MI invasion2/77 (2.6)4/77 (5.2)
<50% MI2/81 (2.5)12/81 (14.8)
≥50% MI2/44 (4.5)17/44 (38.6)
Column total6/202 (3.0)33/202 (16.3)
  • Notes: Each cell reports the number of patients with nodal involvement/total number of patients in the cell (cell percentage). For patients who underwent both sentinel lymph node (SLN) biopsy and systematic lymphadenectomy, only data regarding SLN are reported.

  • ITC, isolated tumor cells; Macro, macrometastases; MI, myometrial invasion; Micro, micrometastases.